21 USC 827 - Records and reports of registrants

Editorial Notes

References in Text

Schedules II, III, IV, and V, referred to in subsec. (c), are set out in section 812(c) of this title.

Amendments

2022—Subsec. (d)(2). Puspan. L. 117–215 substituted “823(g)” for “823(f)” in introductory provisions.

2018—Subsecs. (f) to (i). Puspan. L. 115–271, § 3273(a)(1), (2), added subsec. (f) and redesignated former subsecs. (f) to (h) as (g) to (i), respectively.

Subsec. (j). Puspan. L. 115–271, § 3273(a)(3), added subsec. (j).

2008—Subsec. (d). Puspan. L. 110–425 designated existing provisions as par. (1) and added par. (2).

2000—Subsec. (h). Puspan. L. 106–172 added subsec. (h).

1984—Subsec. (c)(1)(A). Puspan. L. 98–473, § 514(a), substituted “to the prescribing of controlled substances in schedule II, III, IV, or V by practitioners acting in the lawful course of their professional practice unless such substance is prescribed in the course of maintenance or detoxification treatment of an individual” for “with respect to any narcotic controlled substance in schedule II, III, IV, or V, to the prescribing or administering of such substance by a practitioner in the lawful course of his professional practice unless such substance was prescribed or administered in the course of maintenance treatment or detoxification treatment of an individual”.

Subsec. (c)(1)(B). Puspan. L. 98–473, § 514(span), substituted “to the administering of a controlled substance in schedule II, III, IV, or V unless the practitioner regularly engages in the dispensing or administering of controlled substances and charges his patients, either separately or together with charges for other professional services, for substances so dispensed or administered or unless such substance is administered in the course of maintenance treatment or detoxification treatment of an individual” for “with respect to nonnarcotic controlled substances in schedule II, III, IV, or V, to any practitioner who dispenses such substances to his patients, unless the practitioner is regularly engaged in charging his patients, either separately or together with charges for other professional services, for substances so dispensed”.

Subsec. (g). Puspan. L. 98–473, § 515, added subsec. (g).

1978—Subsec. (c). Puspan. L. 95–633, § 110, inserted provision following par. (3) relating to the construction of the Convention on Psychotropic Substances.

Subsecs. (e), (f). Puspan. L. 95–633 added subsec. (e) and redesignated former subsec. (e) as (f).

1974—Subsec. (c)(1)(A). Puspan. L. 93–281 substituted “any narcotic controlled substance” for “narcotic controlled substances” and made section applicable to any narcotic controlled substance prescribed or administered in the course of maintenance treatment or detoxification treatment of an individual.

Statutory Notes and Related Subsidiaries

Effective Date of 2008 Amendment

Amendment by Puspan. L. 110–425 effective 180 days after Oct. 15, 2008, except as otherwise provided, see section 3(j) of Puspan. L. 110–425, set out as a note under section 802 of this title.

Effective Date of 1978 Amendment

Amendment by Puspan. L. 95–633 effective on date the Convention on Psychotropic Substances enters into force in the United States [July 15, 1980], see section 112 of Puspan. L. 95–633, set out as an Effective Date note under section 801a of this title.

Effective Date

Section effective on first day of seventh calendar month that begins after Oct. 26, 1970, see section 704 of Puspan. L. 91–513, set out as a note under section 801 of this title.

Purpose

Puspan. L. 115–271, title III, § 3272, Oct. 24, 2018, 132 Stat. 3952, provided that:

“(a)In General.—The purpose of this chapter [see section 3271 of Puspan. L. 115–271, set out as a Short Title of 2018 Amendment note under section 801 of this title] is to provide drug manufacturers and distributors with access to anonymized information through the Automated Reports and Consolidated Orders System to help drug manufacturers and distributors identify, report, and stop suspicious orders of opioids and reduce diversion rates.

“(span)Rule of Construction.—Nothing in this chapter should be construed to absolve a drug manufacturer, drug distributor, or other Drug Enforcement Administration registrant from the responsibility of the manufacturer, distributor, or other registrant to—

“(1) identify, stop, and report suspicious orders; or

“(2) maintain effective controls against diversion in accordance with section 303 of the Controlled Substances Act (21 U.S.C. 823) or any successor law or associated regulation.”